Cephalon reports Phase II NHL, AML data
CEPH reported data from open-label Phase II trials of two of its compounds: Treanda bendamustine to treat non-Hodgkin's lymphoma (NHL) and CEP-701 to treat acute myelogenous leukemia (AML). Preliminary data from 44 patients with FLT3 mutations showed that 10 of 22 patients given chemotherapy plus CEP-701 had a complete response versus six of 22 patients given chemotherapy alone. CEP-701 is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor.
In a study of Treanda plus Rituxan rituximab in 43 evaluable patients, the objective response rate was 84%, including a 21% complete response rate and a 63% partial response rate. In another trial in 75 patients, Treanda gave an objective response rate of 74%, including a 35% complete response rate and a 39% partial response rate. CEPH gained the alkylating agent through its acquisition of Salmedix earlier this year. ...